Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

COVID-19

Chronic Hand Eczema

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Case-Based Roundtable

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Polls

Editorial Advisory Board

Partners

Subscribe

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and is now finishing her Masters in Digital Media through Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family.

Articles

Research suggested acne is primarily inflammatory, occurring even in unaffected skin, redefining its pathophysiology.

Study Reveals 90% Acne Severity Reduction with TF-LDM

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

ENS-002 targets S. aureus in atopic dermatitis.

Concerto Biosciences Doses First Participant in Phase 1 Trial of ENS-002, a Microbiome-Based Therapy for Atopic Dermatitis

The drug is the first FDA-approved treatment for moderate to severe HS that selectively inhibits both IL-17A and IL-17F.

FDA Approves Bimekizumab for Adults with Moderate to Severe HS

Kaitlyn Bader is the assistant managing editor of 

 and joined the MJH Life Sciences team in June 2022. She attended Otterbein University in Westerville, Ohio, and earned a Bachelor of Arts degree in literary studies with minors in creative writing and film studies. Prior to health care news, Kaitlyn worked in industrial marketing. She enjoys cooking, reading, and tending to her house plants.

Benjamin Lockshin, MD, FAAD, discussed combining biologics with topical innovations like tapinarof and roflumilast to address plaque psoriasis treatment gaps.

Integrating Nonsteroidal Topical Therapies in Plaque Psoriasis Care

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

View

Efficacy and Safety of Subcutaneous Spesolimab for the Prevention of Generalised Pustular Psoriasis Flares (Effisayil 2): an International, Multicentre, Randomised, Placebo-Controlled Trial

Video Series

Revolutionizing GPP Management: The Efficacy and Safety of Spesolimab in Preventing Life-Threatening Flares

Videos

Bruce Strober, MD, PhD, introduces an upcoming series highlighting a clinical trial focused on the efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares.

Explore the groundbreaking findings from the Effisayil 2 trial on the efficacy and safety of subcutaneous spesolimab in preventing flares of generalized pustular psoriasis.

Delve into the complexities of generalized pustular psoriasis (GPP), a rare and life-threatening skin condition, and explore how the monoclonal antibody spesolimab is being investigated to prevent severe, unpredictable flares.

Study Objectives and Key Inclusion Criteria for GPP Patients 

I'm sorry, but it seems there is no article provided for me to summarize and extract key takeaways from. Could you please provide the text of the article

Revolutionizing GPP Management: The Efficacy and Safety of Spesolimab in Preventing Life-Threatening Flares

EP: 1.Revolutionizing GPP Management: The Efficacy and Safety of Spesolimab in Preventing Life-Threatening Flares

EP: 2.Study Objectives and Key Inclusion Criteria for GPP Patients